Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252212104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Styliani Kokoris und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematology and Blood Bank Unit, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, …. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Thrombosis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Paroxysmal Nocturnal Hemoglobinuria (PNH) constitutes a rare bone marrow failure syndrome characterized by hemolytic anemia, thrombotic events (TEs), and bone marrow aplasia of variable degrees. Thrombosis is one of the major clinical manifestations of the disease, affecting up to 40% of individuals with PNH. Venous thrombosis is more prevalent, affecting mainly unusual sites, such as intrabdominal and hepatic veins. TEs might be the first clinical manifestation of PNH. Complement activation, endothelial dysfunction, hemolysis, impaired bioavailability of nitric oxide, and activation of platelets and neutrophils are implicated in the pathogenesis of TEs in PNH patients. Moreover, a vicious cycle involving the coagulation cascade, complement system, and inflammation cytokines, such as interleukin-6, is established. Complement inhibitors, such as eculizumab and ravulizumab (C5 inhibitors), have revolutionized the care of patients with PNH. C5 inhibitors should be initiated in patients with PNH and thrombosis, while they constitute a great prophylactic measure for TEs in those individuals. Anticoagulants, such as warfarin and low-molecular-weight heparin, and, in selected cases, direct oral anticoagulants (DOACs) should be used in combination with C5 inhibitors in patients who develop TEs. Novel complement inhibitors are considered an alternative treatment option, especially for those who develop extravascular or breakthrough hemolysis when terminal inhibitors are administered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Hematology and Blood Bank Unit, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
- Department of Hematology and Lymphoma, BMT Unit, Evangelismos General Hospital, 10676 Athens, Greece.
- Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
- Department of Transfusion Service and Clinical Hemostasis, "Saint Savvas" Oncology Hospital, 11522 Athens, Greece.
- Hematology Laboratory-Blood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
- Department of Hemostasis and Thrombosis, University of Basel, 4001 Basel, Switzerland.
ORCID-Profile: Styliani Kokoris, Paschalis Evangelidis, Serena Valsami, Dimitrios A Tsakiris, Eleni Gavriilaki
Zitieren
APA
Kokoris, S., Polyviou, A., Evangelidis, P., Grouzi, E., Valsami, S., Tragiannidis, K., Gialeraki, A., Tsakiris, D. A., & Gavriilaki, E. (2024). Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212104
Vancouver
Kokoris S, Polyviou A, Evangelidis P, Grouzi E, Valsami S, Tragiannidis K, et al. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212104
BibTeX
@article{Kokoris2024,
author = {Kokoris, Styliani and Polyviou, Antri and Evangelidis, Paschalis and Grouzi, Elisavet and Valsami, Serena and Tragiannidis, Konstantinos and Gialeraki, Argyri and Tsakiris, Dimitrios A and Gavriilaki, Eleni},
title = {Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252212104}
}
EUVIMED